Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacoeconomics
Main Authors: Wallace, Katrine, Goble, Sandra, Isaacson, Jeff, Maloney, Lara, Cameron, Terri, Bedel, Josh
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2019
Assuntos:
Letter to the Editor
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830408/
https://ncbi.nlm.nih.gov/pubmed/31172449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-019-00815-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares